Revance Therapeutics Inc (RVNC)
2.83
-0.06
(-2.08%)
USD |
NASDAQ |
May 31, 16:00
2.83
0.00 (0.00%)
After-Hours: 20:00
Revance Therapeutics Gross Profit (TTM): 163.54M for March 31, 2024
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 163.54M |
December 31, 2023 | 159.80M |
September 30, 2023 | 133.88M |
June 30, 2023 | 114.80M |
March 31, 2023 | 96.82M |
December 31, 2022 | 80.90M |
September 30, 2022 | 72.56M |
June 30, 2022 | 68.14M |
March 31, 2022 | 62.67M |
Date | Value |
---|---|
December 31, 2021 | 54.39M |
September 30, 2021 | 43.79M |
June 30, 2021 | 32.68M |
March 31, 2021 | 19.58M |
December 31, 2020 | 10.56M |
September 30, 2020 | 3.175M |
June 30, 2020 | 0.471M |
March 31, 2020 | 0.193M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
0.193M
Minimum
Mar 2020
163.54M
Maximum
Mar 2024
65.76M
Average
62.67M
Median
Mar 2022
Gross Profit (TTM) Benchmarks
AbbVie Inc | 33.88B |
Design Therapeutics Inc | -- |
Humacyte Inc | -- |
Context Therapeutics Inc | -- |
AN2 Therapeutics Inc | -- |